글로벌 혈우병 A 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

미국 질병통제예방센터(CDC)에 따르면 혈우병은 살아있는 남자아이 5,617명 중 약 1명에게 영향을 미칩니다. 미국에서는 30,000명에서 33,000명의 남성이 혈우병을 앓고 있습니다. 중증 혈우병 A는 진단받은 사람의 절반 이상에게 영향을 미칩니다. 혈우병 A는 혈우병 B보다 4배 더 많은 사람에게 영향을 미칩니다. 혈우병은 모든 인종과 민족의 사람들에게 영향을 미치는 혈액 질환입니다. 일반적으로 고전적 혈우병으로 알려진 혈우병 A는 혈액 내 인자 VIII의 결핍으로 인해 발생하는 유전적 출혈 질환입니다.

Data Bridge Market Research는 2021년 혈우병 A 치료 시장이 111억 달러 규모였으며 2029년까지 177억 7천만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 6.06%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

Hemophilia A is an inherited bleeding disorder that causes blood to coagulate abnormally. People with hemophilia A will bleed more than usual after an injury, surgery, or dental procedure. Hemophilia A is caused by a protein called factor VIII being deficient. Replacement therapy is the most common treatment in which clotting factor VIII is gently dripped or injected into a vein. Emicizumab is presently the only licensed nonfactor therapy that helps with venous access difficulties, frequent bleeds, and other issues, according to the National Center for Biotechnology Information (NCBI). This treatment is also recommended to prevent bleeding in individuals taking inhibitors and having surgery. Following recent improvements, these new medicines show potential hemostatic qualities and enable considerable decreases in bleeding episodes in hemophilia patients with or without inhibitors. DDAVP (desmopressin acetate) is a synthetic version of vasopressin. This natural antidiuretic hormone helps to halt bleeding because of its clinical efficacy and safety and the availability of a concentrated formulation for intravenous and nasal administration.

Hemophilia A Treatment Market Dynamics

Drivers

• High prevalence rate of hemophilia across the globe

The rise in prevalence rate of hemophilia across the globe will act as a major driver that will result in the expansion of the market's growth rate. Patients with severe hemophilia require a frequent hemophilia treatment regimen to keep enough clotting factors in their bloodstream to avoid bleeds. Including a global study published in October 2021 by the World Federation of Hemophilia, there were 209,614 persons diagnosed with hemophilia worldwide, with 165,379 hemophilia A patients. Furthermore, patients who receive quality care are more likely to have fewer co-morbid diseases and have a decreased risk of serious bleeding. As a result, the ever-increasing number of patients has increased demand for haemophilia therapy, which will raise product adoption rates.

• Surging number of pediatric population

The increasing number of pediatric population is estimated to enhance the market's growth rate during the forecast period of 2022-2029. The prevalence of hemophilia is steadily rising among pediatric. Hemophilia is expected to affect one out of every 10,000 births, according to the World Federation of Hemophilia (WFH). Pediatric with hemophilia lack enough clotting factors in their blood as they cannot stop bleeding, necessitating the use of specific hemophilia medications to prevent excessive bleeding. A number of government and non-government groups are launching public awareness campaigns about the signs, diagnosis, and treatment of hemophilia in pediatrics. Furthermore, prominent industry players are focusing on developing innovative solutions to minimize the severity of hemophilia in pediatrics, hence accelerating market growth.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hemophilia A treatment market. Additionally, changing lifestyle of people and growing government favourable initiatives will result in the expansion of hemophilia A treatment market. Another significant factor influencing the growth rate of hemophilia A treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hemophilia A treatment market growth. BioMarin Pharmaceutical Inc. stated in 2021 that it had completed a large phase 3 gene therapy trial in adults with severe hemophilia A in the United States. Over the projection period, such continuous research and innovation initiatives are expected to boost market demand. As a result, the variables listed above are expected to boost product uptake in the country.

• New product launches

Over the projected period, new product launches by industry players in the hemophilia A treatment market are estimated to promote new market opportunities. For illustration, the European Commission granted Novo Nordisk marketing approval for 'Esperoct' in Europe in June 2019. Turoctocog alfa pegol, N8-GP, is marketed under the trade name Esperoct and is used to treat hemophilia A in adolescents and adults (congenital factor VIII deficiency). Furthermore, Roche Products India Pvt. Ltd released Hemlibra, a hemophilia A medication, in India in April 2019. Through Factor VIII inhibitors, it is suggested for preventative therapy of hemophilia A patients to reduce the frequency of bleeding episodes.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hemophilia A treatment market growth during the forecast period.

Restraints/Challenges

• High cost associated with the hemophilia A treatment

The high cost associated with the treatment will obstruct the growth rate of hemophilia A market during the forecast period of 2022-2029. According to the National Hemophilia Foundation, the average cost of hemophilia treatment is over USD 300,000 per year, which has a substantial influence on operation margins, especially in today's capitated reimbursement environment. Due to the high costs associated with clotting factor therapy, market expansion in emerging nations with comparatively low income levels may be impeded.

On the other hand, the lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the hemophilia A treatment market. Additionally, strict government policies and lack of awareness about the treatment will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hemophilia A treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemophilia A treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

After von Willebrand disease, hemophilia A is the most common X-linked recessive condition and the most common inherited clotting factor deficiency. Males are more likely to be affected by hemophilia A, however, females can be impacted as well. Hemophilia A affects about 1 in every 5,000 new-born boys. Hemophilia A affects approximately 60% of people. Hemophilia affects people of all races and ethnic groups equally.

Hemophilia A treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hemophilia A Treatment Market

Due to disruptions in the worldwide supply chain and logistics, the onset of the COVID-19 pandemic had a minor negative influence on the hemophilia treatment market. The impact of the coronavirus outbreak on the sector peaked in early 2020, when people with such disorders were more susceptible to infectious diseases and hence had a higher risk of contracting coronavirus. Several organizations, hospitals, and haematologists, on the other hand, were working hard to manage the COVID-19 public health issue. For instance, in response to the coronavirus outbreak, the American Society of Hematology established a forum for the exchange of useful, precise, and up-to-date information to aid haematologists. As a result, such approaches are predicted to aid in the restoration of treatment volume following the COVID-19 outbreak.

Recent Development

• In February 2020, Novo Nordisk had announced the launch of the long-acting recombinant factor VIII product named ESPEROCT. It used to prevent as well treat bleeding in individuals suffering from hemophilia A. The new therapy is generally used for routine prophylaxis, which further decreases bleeding episodes, on-demand treatment, control of bleeding episodes, and perioperative management of bleeding.

Global Hemophilia A Treatment Market Scope

The hemophilia A treatment market is segmented on the basis of type, product, demographic, treatment, diagnosis, therapy, drug class, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Severe
• Moderate
• Mild

Product

• Recombinant Factor Concentrates
  • Factor VIII
  • Factor IX
• Plasma-derived Factor Concentrates
  • Factor VIII
  • Factor IX
• Extended Half-life Products
  • Factor VIII
  • Factor IX

Demographic

• Pediatric
  • 0 to 4
  • 5 to 13
  • 14 to18
• Adult
  • 19 to 44
  • 45+

Diagnosis

• Genetic Testing
• Fibrinogen Test
• Factor VIII and Factor IX Tests
• Prothrombin Time (PT)
• Complete Blood Count (CBC)

Treatment

• Prophylaxis
• On Demand

요법

• 요인 대체 요법
• 비인자 대체 요법

약물 종류

• 바소프레신
• 응고 인자

투여 형태

• 주입
• 솔루션
• 기타

투여 경로

• 비경구적
• 비강 스프레이
• 기타

최종 사용자

• 병원
• 전문 클리닉
• 홈케어
• 기타

유통 채널

• 병원 약국
• 소매 약국
• 온라인 약국
• 기타

혈우병 A 치료 시장 지역 분석/통찰력

혈우병 A 치료 시장을 분석하고, 위에 언급된 대로 국가, 유형, 제품, 인구 통계, 치료, 진단, 요법, 약물 종류, 투여 형태, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

혈우병 A 치료 시장 보고서에서 다루는 국가는 북미의 미국, 캐나다 및 멕시코, 유럽의 독일, 프랑스, ​​영국, 네덜란드, 스위스, 벨기에, 러시아, 이탈리아, 스페인, 터키, 유럽의 기타 유럽, 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 아시아 태평양(APAC)의 기타 아시아 태평양(APAC), 사우디 아라비아, UAE, 남아프리카, 이집트, 이스라엘, 중동 및 아프리카(MEA)의 일부인 기타 중동 및 아프리카(MEA), 남미의 일부인 기타 남미, 브라질, 아르헨티나입니다.

북미는 시장 점유율과 시장 수익 측면에서 혈우병 A 치료 시장을 지배하고 있으며 예측 기간 동안 지배력을 계속 유지할 것입니다. 이는 주요 핵심 기업이 존재하기 때문이며, 증가하는 의료 지출은 이 지역의 시장 성장률을 더욱 촉진할 것입니다. 또한 연구 개발 활동이 증가함에 따라 이 지역의 시장 성장률이 더욱 촉진될 것입니다. 

아시아 태평양 지역은 이 지역에서 혈우병 A에 대한 새로운 치료법 승인이 증가함에 따라 2022-2029년 예측 기간 동안 성장할 것으로 예상됩니다. 또한, 의료 인프라의 개발과 정부 이니셔티브의 확대는 이 지역의 시장 성장률을 더욱 촉진할 것입니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 혈우병 A 치료 시장 점유율 분석

혈우병 A 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 혈우병 A 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

혈우병 A 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 머크앤코(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 백스터(미국)
• 다케다제약 주식회사(일본)
• 그리폴스, SA(스페인)
• CSL(미국)
• 바이오마린(미국)
• Spark Therapeutics, Inc. (미국)
• 추가이제약 주식회사(일본)
• Octapharma AG(스위스)
• Novo Nordisk A/S(덴마크)
• 바이오젠(미국)
• 제넨텍 주식회사(미국)
• Bayer AG(독일)
• 페링 BV(스위스)

SKU-56926